BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/17/2023 8:49:01 AM | Browse: 35 | Download: 4
Publication Name World Journal of Diabetes
Manuscript ID 88354
Country/Territory China
Category Endocrinology & Metabolism
Manuscript Type Basic Study
Article Title Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1a and inhibiting the RhoA/ROCK pathway
Manuscript Source Unsolicited Manuscript
All Author List Na Li, Qiu-Xiao Zhu, Gui-Zhi Li, Ting Wang and Hong Zhou
Funding Agency and Grant Number
Funding Agency Grant Number
Health Commission of Hebei Province 20210196
S&T Program of Hebei 22377726D
Corresponding Author Hong Zhou, PhD, Chief Physician, Doctor, Department of Endocrinology, The Second Hospital of Hebei Medical University, No. 215, Heping West Road, Shijiazhuang 050000, Hebei Province, China. zhoubs2013@163.com
Key Words Empagliflozin; Diabetic cardiomyopathy; AMPK; ROCK; Apoptosis; Oxidative stress
Core Tip We established a diabetic cardiomyopathy model in db/db mice and treated the mice with empagliflozin for 8 wk, and found that empagliflozin observably improved cardiac function in diabetic mice, which was maybe related to activation of AMP-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1a) and inhibition of the RhoA/ROCK pathway. In order to exclude the effects of metabolic improvement on the heart in vivo, in vitro experiment in high glucose conditions was performed. The results confirmed that the anti-oxidative stress and anti-apoptotic effects of empagliflozin on cardiomyocytes were achieved by activating AMPK/PGC-1a and inhibiting ROCK. Furthermore, the effects were independent of sodium-glucose cotransporter (SGLT)2 inhibition as no SGLT2 expression was detected on cardiomyocytes.
Citation Li N, Zhu QX, Li GZ, Wang T, Zhou H. Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1 and inhibiting the RhoA/ROCK pathway. World J Diabetes 2023; In press
2023-09-21 13:29
Peer-Review Started
2023-09-21 13:30
To Make the First Decision
Return for Revision
2023-10-10 08:48
2023-10-20 11:50
Second Decision
2023-11-14 01:15
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2023-11-17 08:49
Articles in Press
2023-11-17 08:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
2023-11-13 02:53
Typeset the Manuscript
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Assistant Editor Assistant Editor
Science Editor Cong Lin
Reviewer Code 06139840, 02817134, 02991481, and 02817134
Editorial Director
Journal Chief Editor
Company Chief Editor Jin-Lei Wang
Language Editor Tian-Qi Wang
Production Editor
Responsible Production Editor
Responsible Science Editor
Proofing Editorial Director Jin-Lei Wang
Proofing Editor-in-Chief Lian-Sheng Ma